Bayer Wins Two Bullish Calls, but Only One of Them Expects a Profit Beat
Published on 10/17/2026 at 13:01 | Editorial boerse-global.de
Two of Europe's most closely watched equity houses have reaffirmed their confidence in Bayer this week, yet their notes point to a subtler story than the headline recommendations suggest. JPMorgan's Richard Vosser kept his "Overweight" rating and a 61-euro price target, while UBS maintained its buy case with a 62-euro objective. Against Friday's close of €44.19, both imply substantial upside. What separates the two calls — and what matters more for anyone holding the stock into the autumn — is how each firm frames the gap between Bayer's pharmaceutical momentum and the hard numbers underneath it.
Revenue optimism, profit caution
Vosser's stance is not a blanket endorsement of the earnings trajectory. He splits his forecast along a clean line: sales should land 2% above consensus, but EBITDA is pencilled in 6% below it. He also expects management to stand by its full-year guidance. Those two positions can coexist comfortably — a confirmed outlook does not erase a softer operating result, and a weaker-than-consensus EBITDA is entirely compatible with guidance being held.
UBS, for its part, leans on a different axis. The bank flagged the well-documented weakness in Bayer's agricultural division while pointing to intact trends through fiscal 2026 and 2027, and it continues to see dynamism in the pharmaceuticals business. Its positive view therefore rests on the diverging fortunes of the individual segments rather than on any assumption that the crop-science drag has already been resolved. Progress in medicine does not, on this reading, translate automatically into a recovery in agriculture.
Pipeline news arrives in different stages
The recent flow of company announcements gives both houses something to point to — provided one keeps the regulatory milestones straight.
Should investors sell immediately? Or is it worth buying Bayer?
Roughly a week ago, the US Food and Drug Administration accepted Bayer's supplementary application for Finerenon, marketed as Kerendia, covering the treatment of chronic kidney disease without diabetes. The filing draws on positive Phase III results from the FIND-CKD trial. Acceptance is a procedural step in the review process; it is not an approval, and it says nothing about near-term operating profit.
Separately, Bayer's wholly owned subsidiary Vividion began a global Phase II study of VVD-214 in combination with Pembrolizumab, dosing its first patient. The trial enrols previously untreated patients with advanced MSI-H or dMMR colorectal cancer. Vividion operates independently under the Bayer umbrella, and the study's launch extends the clinical development of the compound without yet offering proof of efficacy from this investigation.
On the investment side, Bayer has announced a $2.2 billion commitment to a new pharmaceutical production site in New Albany, Ohio, expected to create around 600 jobs. That, too, is a declared intention rather than a completed outlay — a long-horizon item that sits alongside the short-term earnings question rather than answering it.
Bayer at a turning point? This analysis reveals what investors need to know now.
November 3 is the real scorecard
Bayer publishes its third-quarter 2026 results on November 3, giving investors the first hard test of whether JPMorgan's projected combination — stronger revenue, softer EBITDA — actually materialises. The date also offers the opportunity to weigh the pharma division's positive momentum against the agricultural weakness UBS has flagged.
For shareholders, the takeaway is that neither note is a simple buy-and-forget signal. The recommendations remain analyst opinions, and their assumptions — revenue outperformance, resilient pharma trends, a farm business still under pressure — will be measured against reported figures in early November. What counts then is not just the top line, but the operating result and the annual outlook that accompanies it.
Ad
Bayer Stock: New Analysis - 17 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
